There are 1105 resources available
Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Presenter: Byoung Chul Cho
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Presenter: Kosei Hasegawa
Session: ESMO 2024 Highlights session 2
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Presenter: Bin-Chi Liao
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Presenter: Wen Yee Chay
Session: ESMO 2024 Highlights session 2
Resources:
Slides
Webcast
Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III Unicancer trial
Presenter: Sofia Rivera
Session: ESMO 2024 Highlights session 2
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
Presenter: Senthil Jagannathan Rajappa
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III Unicancer trial
Presenter: Faye Lim
Session: ESMO 2024 Highlights session 2
Resources:
Slides
Webcast
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
Presenter: Rebecca Dent
Session: ESMO 2024 Highlights session 2
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (C-P) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy
Presenter: Krittiya Korphaisarn
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
Presenter: Soo Chin Lee
Session: ESMO 2024 Highlights session 2
Resources:
Slides
Webcast